| Sign In to gain access to subscriptions and/or personal tools. |
Simulated Driving Changes in Young Adults With ADHD Receiving Mixed Amphetamine Salts Extended Release and AtomoxetineCognitive Research Corporation, gkay{at}cogres.com
Astellas Pharma U.S., Inc
Washington Neuropsychological Institute
Background: Psychostimulant treatment may improve simulated driving performance in young adults with attention-deficit/hyperactivity disorder (ADHD). Method: This was a randomized, double-blind, placebo-controlled, crossover study of simulated driving performance with mixed amphetamine salts—extended release (MAS XR) 50 mg/day (Cohort 1) and atomoxetine 80 mg/day (Cohort 2) in young adults with ADHD. Results: Adults aged 19 to 25 years with AD/HD (N = 19) who were administered MAS XR significantly improved overall simulated driving performance versus placebo up to 12 hours after dosing. In contrast, there were no statistically significant differences in simulated-driving-performance scores between atomoxetine and placebo. At endpoint, MAS XR reduced ADHD Rating Scale scores
Key Words: simulated driving performance • attention-deficit/hyperactivity disorder • adults • psychostimulant • AD/HD • ADHD
This version was published on January
1, 2009 Journal of Attention Disorders, Vol. 12, No. 4,
316-329 (2009) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
30% in 80% of subjects, whereas atomoxetine achieved this level of improvement for 40%. Limitations: Small sample size and use of simulated driving may limit generalizability of the findings. Conclusion: MAS XR in young adults with ADHD yields significant improvements in simulated driving performance and ADHD symptoms. (J. of Att. Dis. 2009; 12(4) 316-329)